卵巢上皮癌

  • 网络Epithelial Ovarian Cancer
卵巢上皮癌卵巢上皮癌
  1. 血清CA(125)测定在卵巢上皮癌中的应用价值

    The Practical Value that Detection of Serum CA_ ( 125 ) in Epithelial Ovarian Cancer

  2. 目的:探讨血清中CA125和CA199联合检测在卵巢上皮癌和子宫内膜异位症中的临床价值。

    Objective : To explore the expression of CA125 and CA199 in epithelial ovarian cancer and endometriosis discuss its clinical significance .

  3. 卵巢上皮癌的CT诊断

    CT diagnosis of carcinomas of ovary

  4. CA(125)测定联合B超检查对卵巢上皮癌的诊断和预后的价值分析

    Evaluation of CA_ ( 125 ) and ultrasound in diagnosis and prognosis of ovarian epithelial carcinoma

  5. 卵巢上皮癌术后化疗期间血清CA(125)检测与其预后关系的研究

    Study on the relationship between serum CA_ ( 125 ) of postoperative chemotherapy and prognosis of epithelial ovarian carcinoma

  6. 分析核DNA含量、p53蛋白表达与卵巢上皮癌患者CT表现及生存期的关系。

    The correlation of nuclear DNA content and p53 protein expression with CT findings and prognosis of EOT patients was analyzed .

  7. Fas及其配体在卵巢上皮癌和正常卵巢上皮细胞表达的研究

    Expression of Fas and Fas Ligand in normal ovarian epithelium and ovarian cancer

  8. 术前血清CRP测定对评估卵巢上皮癌预后的价值

    Prognostic Value of Preoperative Serum C-reactive Protein in Patients with Epithelial Ovarian Cancer

  9. 卵巢上皮癌组织中HLA抗原和CD80的表达

    Expression and clinical significance of HLA antigen and CD80 in ovarian epithelial carcinoma

  10. 卵巢上皮癌组织中survivin的表达及其与Fas、FasL表达的关系

    Expression of Survivin in Ovarian Epithelial Carcinoma and Its Correlation with Expression of Fas and FasL

  11. 卵巢上皮癌组织中HLAⅠ类抗原和CD54的表达及临床意义

    Expression and clinical significance of HLA class ⅰ antigens and CD54 in ovarian epithelial cancer

  12. 铂类耐药性卵巢上皮癌患者卵巢上皮中VEGF-C表达的研究

    Expression of VEGF-C protein in platinum-resistant epithelial ovarian cancer

  13. 结论Survivin蛋白表达水平增高可能与卵巢上皮癌的分化转移有关。

    Conclusion High expression of Survivin protein may be related with the differentiation and metastasis of epithelial ovarian carcinoma .

  14. 高聚金葡素辅佐化疗药物对卵巢上皮癌者外周血T细胞亚群及NK细胞活性的影响

    Effects of HASL plus chemotherapy on peripheral blood T cell subsets and NK cell activity in patients with ovarian epithelial carcinoma

  15. 中、晚期卵巢上皮癌242例用CP、CPT、CAP三方案化疗疗效及预后分析比较

    Comparative Analysis of the Results from Treatment and Prognosis on CP , CTP and CAP Regimens for Advanced Ovarian Epithelial Cancer

  16. 卵巢上皮癌组织中LRP和P-gp表达及其临床意义

    Expression of Lung Resistance Protein and P glycoprotein and Clinical Significance in Epithelial Ovarian Tumor

  17. 目的:探讨溶血磷脂酸(lysophosphatidicacid,LPA)及其3种受体亚型(LPA1、LPA2、LPA3)在卵巢上皮癌发生和发展中的作用及可能机制。

    Objective : To evaluate effects of lysophosphatidic acid ( LPA ) and its receptors on the carcinogenesis of epithelial ovarian carcinoma .

  18. 卵巢上皮癌中HLA-DR及HLA-ABC表达的临床意义

    Clinical Significance of Expression of HLA-DR and HLA-ABC Antigens in Epithelial Ovarian Carcinoma

  19. LPA及其受体与IL-6、IL-8在卵巢上皮癌中的表达及其临床意义

    The Expression of LPA Receptors in Epithelial Ovarian Carcinoma Tissues and Plasma LPA , IL-6 and IL-8 Levels in Patients with Epithelial Ovarian Carcinoma

  20. 体外MTT法预测卵巢上皮癌化疗药敏性与体内疗效相关性的评估

    The Evaluation of MTT Assay in vitro for Prediction of the Correlativity between the sensitivity of Chemotherapeutic Agents in vitro and the Effect in vivo on Ovarian Epithelial Carcinoma

  21. 卵巢上皮癌Ⅲ期术后≤2cm残留灶的治疗与预后

    Stage ⅲ epithelial ovarian cancer with residual tumor ≤ 2 ? Cm after primary surgery

  22. 结论:MTT法对卵巢上皮癌的个体化治疗计划有参考价值,能在一定程度上指导临床用药。

    Conclusion : The MTT assay in vitro has a referenced value for the individualized regimens on ovarian epithelioma and can , to some extent , direct the clinical medication .

  23. 目的:探讨卵巢上皮癌组织中环氧合酶-2(COX-2)表达及其与微血管密度(MVD)的关系。

    Objectives : To research the expressions of cyclooxygenase-2 ( COX-2 ) in cancer tissues of human epithelial ovarian and its relations with the microvascular density ( MVD ) .

  24. 卵巢上皮癌组患者血清TSGF水平高于其他类型卵巢癌;

    The levels of TSGF in the patients with epithelial ovarian cancer than those with any other types of ovarian cancer ;

  25. 结论IFO联合化疗是治疗复发或未控、特别是对PDD敏感的卵巢上皮癌、宫颈鳞癌以及子宫肉瘤的有效方案。

    Conclusion IFO combination chemotherapy is effective in treating recurrent or progressive gynecologic malignancies , especially PDD sensitive ones .

  26. 异环磷酰胺联合自体PHA-LAK细胞治疗晚期复发卵巢上皮癌的疗效观察

    Ifosfamide with PHA-LAK cell adoptive immunotherapy in advanced recurrent ovarian epithelial cancer

  27. 方法从1984年1月至1998年12月治疗Ⅲ、Ⅳ期卵巢上皮癌120例。病例除手术治疗外还全部用FPM(5-Fu、DDP、MMC)化疗方案化疗。

    Methods From Jan.1984 to Dec.1998 , 120 patients with stage ⅲ and stage ⅳ ovarian epithelial cancer received chemotherapy of FPM regimen besides surgical treatment .

  28. COX-2及MUC-1的阳性表达与卵巢上皮癌的预后有关(P<0.05);

    The over expression of COX-2 and MUC-1 were also correlated with prognosis of ovarian epithelial carcinoma ( P < 0.05 ) .

  29. 方法运用逆转录聚合酶链反应(RT-PCR)法,测定24例卵巢上皮癌、8例卵巢良性上皮肿瘤组织中LPA受体LPA1、LPA2、LPA3mRNA水平;

    Methods RT-PCR was used to detect the mRNA expression of LPA receptors in the tissues of epithelial ovarian carcinoma ( 24 cases ) and benign epithelial ovarian tumor ( 8 cases ) .

  30. 目的:研究卵巢上皮癌(OEC)组织中人类白细胞抗原Ⅰ(HLAⅠ)、CD54和CD80的表达及其临床意义。

    Objective : To investigate the expressions of human leukocyte antigen class ⅰ( HLA ⅰ), CD54 and CD80 in ovarian epithelial carcinoma ( OEC ) tissues and their clinical significance .